Tourmaline Bio, Inc. (TRML) AI Stock Price Forecast & Investment Analysis
Latest Analysis Date: August 22, 2025
Tourmaline Bio, Inc. (TRML) - Comprehensive Stock Analysis & Investment Research
Company Overview & Business Profile
Tourmaline Bio, Inc. (Stock Symbol: TRML)
is a leading company in the Life Sciences sector
, specifically operating within the Biological Products, (No Diagnostic Substances) industry.
The organization employs approximately 125 professionals worldwide
.
The company has established itself as
an emerging investment opportunity with substantial growth potential.
Financial Performance & Key Metrics Analysis
Market Capitalization: $600 million - Classified as a
small-cap investment offering high growth potential.
Advanced AI Stock Prediction & Price Target Analysis
🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Tourmaline Bio, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.
Market Position & Competitive Advantage Analysis
Tourmaline Bio, Inc. strategically competes in the highly dynamic
Biological Products, (No Diagnostic Substances) marketplace,
representing an emerging small-cap investment with substantial growth potential and market disruption capabilities
.
.
Tourmaline Bio, Inc. Stock Price Chart and Technical Analysis
Loading chart data...
Loading Tourmaline Bio, Inc. interactive price chart and technical analysis...
Deep dive into Tourmaline Bio, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.
Understanding Valuation Metrics
What these metrics mean: Valuation metrics help determine if Tourmaline Bio, Inc. stock is fairly priced compared to its earnings, assets, and market position.
How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.
For Tourmaline Bio, Inc.: With a P/E ratio of -3.46, the market sees the stock as potentially undervalued.
P/E Ratio-3.46x
P/B Ratio2.31x
Market Cap$600M
EPS$-3.44
Book Value/Share$10.08
Understanding Profitability Metrics
What these metrics mean: These ratios measure how efficiently Tourmaline Bio, Inc. converts revenue into profit and generates returns for shareholders.
How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.
For Tourmaline Bio, Inc.:
Understanding Financial Health Metrics
What these metrics mean: These ratios assess Tourmaline Bio, Inc.'s ability to meet short-term obligations and manage debt levels effectively.
How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.
For Tourmaline Bio, Inc.:
Understanding Cash Flow Metrics
What these metrics mean: Cash flow metrics reveal Tourmaline Bio, Inc.'s ability to generate cash from operations and fund growth initiatives.
How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.
For Tourmaline Bio, Inc.:
Understanding Operational Efficiency Metrics
What these metrics mean: These ratios measure how effectively Tourmaline Bio, Inc. uses its assets and manages working capital.
How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.
For Tourmaline Bio, Inc.:
Understanding Financial Statement Data
What these metrics mean: Key figures from Tourmaline Bio, Inc.'s income statement and balance sheet showing absolute financial performance.
How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.
For Tourmaline Bio, Inc.:
Income Statement ($ Millions)
Operating Income$-36M
Net Income$-37M
R&D Expense$26M
Balance Sheet Highlights ($ Millions)
Dividend & Shareholder Information
Shares Outstanding26M
Growth Metrics (YoY)
EPS Growth-60.4%
Tourmaline Bio, Inc. (TRML) Fundamental Analysis & Insider Trading Data
(Quarterly Financial Reports)
Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Tourmaline Bio, Inc. stock analysis.
Loading fundamental data...
Loading Tourmaline Bio, Inc. comprehensive fundamental analysis and insider trading data...
Latest Tourmaline Bio, Inc. Stock News & Market Analysis
Breaking news, analyst reports, and market updates affecting Tourmaline Bio, Inc. (TRML) stock price and investment outlook.
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025 NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline ...
If you want to know who really controls Tourmaline Bio, Inc. (NASDAQ:TRML), then you'll have to look at the makeup of its share registry. We can see that retail investors own the lion's share in ...
– Tourmaline assembles leading experts to support the development of pacibekitug for cardiovascular diseases – – Cardiovascular Scientific Advisory Board expected to provide strategic guidance as ...
Reported positive topline results from the ongoing Phase 2 TRANQUILITY trial of pacibekitug in May 2025, demonstrating rapid, deep, and durable reductions in high-sensitivity C-reactive protein with ...
Shares of Tourmaline Bio, Inc. have surged 200% since its public debut in October 2023. The company's main asset, TOUR006, shows potential as a therapy for thyroid eye disease and atherosclerotic ...
--Tourmaline Bio, Inc., a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory ...
Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has been assigned a consensus rating of “Buy” from the seven brokerages that are covering the firm, Marketbeat Ratings reports.
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically ...
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024 NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology ...
– Tourmaline assembles leading experts to support the development of pacibekitug for cardiovascular diseases – – Cardiovascular Scientific Advisory Board expected to provide strategic guidance as ...
Tourmaline Bio, Inc. Competitors & Peer Analysis - Life Sciences Sector
Comparative analysis of Tourmaline Bio, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.
Frequently Asked Questions - Tourmaline Bio, Inc. Stock Forecast
How accurate are Tourmaline Bio, Inc. stock predictions?
Our AI model demonstrates 21% historical accuracy for TRML predictions, based on advanced machine learning algorithms trained on over 10 years of market data.
What factors influence Tourmaline Bio, Inc. stock price forecasts?
Is Tourmaline Bio, Inc. a good investment in 2025?
Based on our AI analysis, Tourmaline Bio, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.
How often are Tourmaline Bio, Inc. forecasts updated?
Tourmaline Bio, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.
Want More Advanced Tourmaline Bio, Inc. Analysis?
Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Tourmaline Bio, Inc. stock.
